Browse ARHGAP22

Summary
SymbolARHGAP22
NameRho GTPase activating protein 22
Aliases RhoGap22; rho-type GTPase-activating protein 22; Rho GTPase-activating protein 22
Chromosomal Location10q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Nucleus Note=Mainly cytoplasmic. Some fraction is nuclear (By similarity).
Domain PF00169 PH domain
PF00620 RhoGAP domain
Function

Rho GTPase-activating protein involved in the signal transduction pathway that regulates endothelial cell capillary tube formation during angiogenesis. Acts as a GTPase activator for the RAC1 by converting it to an inactive GDP-bound state. Inhibits RAC1-dependent lamellipodia formation. May also play a role in transcription regulation via its interaction with VEZF1, by regulating activity of the endothelin-1 (EDN1) promoter (By similarity).

> Gene Ontology
 
Biological Process GO:0001525 angiogenesis
GO:0048514 blood vessel morphogenesis
GO:0051056 regulation of small GTPase mediated signal transduction
Molecular Function GO:0005096 GTPase activator activity
GO:0008047 enzyme activator activity
GO:0030695 GTPase regulator activity
GO:0060589 nucleoside-triphosphatase regulator activity
Cellular Component GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0030055 cell-substrate junction
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-194840: Rho GTPase cycle
R-HSA-162582: Signal Transduction
R-HSA-194315: Signaling by Rho GTPases
Summary
SymbolARHGAP22
NameRho GTPase activating protein 22
Aliases RhoGap22; rho-type GTPase-activating protein 22; Rho GTPase-activating protein 22
Chromosomal Location10q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ARHGAP22 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolARHGAP22
NameRho GTPase activating protein 22
Aliases RhoGap22; rho-type GTPase-activating protein 22; Rho GTPase-activating protein 22
Chromosomal Location10q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ARHGAP22 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolARHGAP22
NameRho GTPase activating protein 22
Aliases RhoGap22; rho-type GTPase-activating protein 22; Rho GTPase-activating protein 22
Chromosomal Location10q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ARHGAP22 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.8050.0248
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.0530.238
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.6220.366
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.5970.148
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3330.812
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.920.637
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2170.601
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.180.811
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2750.736
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1630.877
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.4310.757
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3090.0344
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ARHGAP22 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.111.8-4.71
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1031066.7-56.70.108
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277304.1-4.10.561
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275905.1-5.10.549
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolARHGAP22
NameRho GTPase activating protein 22
Aliases RhoGap22; rho-type GTPase-activating protein 22; Rho GTPase-activating protein 22
Chromosomal Location10q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ARHGAP22. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolARHGAP22
NameRho GTPase activating protein 22
Aliases RhoGap22; rho-type GTPase-activating protein 22; Rho GTPase-activating protein 22
Chromosomal Location10q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ARHGAP22. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ARHGAP22.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolARHGAP22
NameRho GTPase activating protein 22
Aliases RhoGap22; rho-type GTPase-activating protein 22; Rho GTPase-activating protein 22
Chromosomal Location10q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ARHGAP22. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolARHGAP22
NameRho GTPase activating protein 22
Aliases RhoGap22; rho-type GTPase-activating protein 22; Rho GTPase-activating protein 22
Chromosomal Location10q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ARHGAP22 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolARHGAP22
NameRho GTPase activating protein 22
Aliases RhoGap22; rho-type GTPase-activating protein 22; Rho GTPase-activating protein 22
Chromosomal Location10q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ARHGAP22 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolARHGAP22
NameRho GTPase activating protein 22
Aliases RhoGap22; rho-type GTPase-activating protein 22; Rho GTPase-activating protein 22
Chromosomal Location10q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ARHGAP22 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.